Trials & Tribulations San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress April 14, 2023Vol.49 No.15By Angela DeMichele, Rajarshi Sengupta and Carlos L. Arteaga
Pragmatica-Lung, a landmark pragmatic trial with registrational intent, starts enrollment April 14, 2023Vol.49 No.15By Jacquelyn Cobb
Trials & Tribulations Does salpingectomy prevent ovarian cancer? Let’s prove it.The SOROCk clinical trial, NRG CC008 (NCT04251052) March 17, 2023Vol.49 No.11By Kathryn P. Pennington, Warner K. Huh, Sandra Russo and Joan L. Walker
Cancer patients have sevenfold suicide risk in first six months after diagnosis March 03, 2023Vol.49 No.09By Jacquelyn Cobb
Grant-funded, investigator-initiated trials fail to bounce back from COVID as 50% of research staff left for higher-paying jobs February 17, 2023Vol.49 No.07By Matthew Bin Han Ong
Trials & Tribulations MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial February 03, 2023Vol.49 No.05By Amar U. Kishan
FreeTrials & Tribulations Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization” January 27, 2023Vol.49 No.04By Mark J. Ratain and Garth W. Strohbehn
Conversation with The Cancer Letter City of Hope’s Mustafa Raoof: Medicare Advantage cancer patients more likely to die within 30 days after complex surgery January 20, 2023Vol.49 No.03By Matthew Bin Han Ong
Trials & Tribulations Pancreatic cancer survival edges up—as screening strategies emerge January 20, 2023Vol.49 No.03By Rosario Ligresti
Moderna’s mRNA cancer vaccine improves survival in phase IIb melanoma study—first observation of efficacy in an RCT December 16, 2022Vol.48 No.45By Matthew Bin Han Ong
